Zhonglin Hao

2.9k total citations
57 papers, 2.1k citations indexed

About

Zhonglin Hao is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Zhonglin Hao has authored 57 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 15 papers in Molecular Biology. Recurrent topics in Zhonglin Hao's work include Lung Cancer Research Studies (9 papers), Lung Cancer Treatments and Mutations (8 papers) and Lung Cancer Diagnosis and Treatment (7 papers). Zhonglin Hao is often cited by papers focused on Lung Cancer Research Studies (9 papers), Lung Cancer Treatments and Mutations (8 papers) and Lung Cancer Diagnosis and Treatment (7 papers). Zhonglin Hao collaborates with scholars based in United States, China and Georgia. Zhonglin Hao's co-authors include Jin Xie, Geoffrey D. Wang, Hongmin Chen, Zibo Li, Zipeng Zhen, Baozhong Shen, John K. Cowell, Peng Wang, John C. Herr and Paul W. Biddinger and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Zhonglin Hao

54 papers receiving 2.1k citations

Peers

Zhonglin Hao

PRM

ONCOL

Meng Liang China

Joseph A. Reddy United States

Lucia M.A. Crane Netherlands

D G Kieback United States

Masahide Kuroki Japan

Michelle Dawson United States

Masanobu Komatsu United States

Zhiming Mai United States

Gustavo Helguera United States

Beth Goins United States

Meng Liang China

Zhonglin Hao

294 ×0.4

804 ×1.1

187 ×0.4

PRM

232 ×0.5

ONCOL

190 ×0.5

Citations per year, relative to Zhonglin Hao Zhonglin Hao (= 1×) peers Meng Liang

Countries citing papers authored by Zhonglin Hao

Since Specialization

Citations

This map shows the geographic impact of Zhonglin Hao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhonglin Hao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhonglin Hao more than expected).

Fields of papers citing papers by Zhonglin Hao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhonglin Hao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhonglin Hao. The network helps show where Zhonglin Hao may publish in the future.

Co-authorship network of co-authors of Zhonglin Hao

This figure shows the co-authorship network connecting the top 25 collaborators of Zhonglin Hao. A scholar is included among the top collaborators of Zhonglin Hao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhonglin Hao. Zhonglin Hao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hao, Zhonglin, et al.. (2025). New developments in immunotherapy for SCLC. Journal for ImmunoTherapy of Cancer. 13(1). e009667–e009667. 5 indexed citations

Dong, Huijun, et al.. (2025). A LASSO-based integrative model of serum biomarkers and gene polymorphisms for predicting poor sepsis prognosis. Biomarkers in Medicine. 19(20). 1009–1018.

Hao, Zhonglin, et al.. (2024). Therapeutic potential of tumor-infiltrating lymphocytes in non-small cell lung cancer. Cancer Letters. 605. 217281–217281. 3 indexed citations

Hao, Zhonglin, et al.. (2023). TARGETED THERAPY CHANGING NON-SMALL CELL LUNG CANCER PARADIGM: USE OF ALECTINIB IN STAGE III NSCLC. CHEST Journal. 164(4). A4304–A4305.

Hao, Zhonglin, et al.. (2023). Survival outcomes of stage I small cell lung cancer (SCLC) treated with stereotactic body radiation therapy (SBRT) versus external beam radiation therapy (EBRT): An NCDB analysis.. Journal of Clinical Oncology. 41(16_suppl). e20638–e20638. 1 indexed citations

Harris, Aaron M., et al.. (2022). Extracorporeal Membrane Oxygenation to Facilitate Chemotherapy—Moving the Goalposts!. Cureus. 14(9). e29576–e29576. 1 indexed citations

Brainson, Christine F., Bin Huang, Quan Chen, et al.. (2021). Description of a Lung Cancer Hotspot: Disparities in Lung Cancer Histology, Incidence, and Survival in Kentucky and Appalachian Kentucky. Clinical Lung Cancer. 22(6). e911–e920. 5 indexed citations

Hao, Zhonglin & Peng Wang. (2019). Lenvatinib in Management of Solid Tumors. The Oncologist. 25(2). e302–e310. 87 indexed citations

Habtetsion, Tsadik, Zhi‐Chun Ding, Wenhu Pi, et al.. (2018). Alteration of Tumor Metabolism by CD4+ T Cells Leads to TNF-α-Dependent Intensification of Oxidative Stress and Tumor Cell Death. Cell Metabolism. 28(2). 228–242.e6. 53 indexed citations

10.

Lemmon, Christopher A., et al.. (2017). Angiogenesis and Anti-tumor Immunity in the Tumor Microenvironment: Opportunities for Synergism in Intervention. 3(10). 460. 1 indexed citations

11.

Ding, Zhi‐Chun, Tsadik Habtetsion, Yang Cao, et al.. (2017). Adjuvant IL-7 potentiates adoptive T cell therapy by amplifying and sustaining polyfunctional antitumor CD4+ T cells. Scientific Reports. 7(1). 12168–12168. 22 indexed citations

12.

Hao, Zhonglin, et al.. (2016). Sunitinib: the antiangiogenic effects and beyond. OncoTargets and Therapy. Volume 9. 5495–5505. 82 indexed citations

13.

Hao, Zhonglin & Vamsi Kota. (2015). Volasertib for AML: clinical use and patient consideration. OncoTargets and Therapy. 8. 1761–1761. 14 indexed citations

14.

Ren, Mingqiang, Mei Hong, Gentao Liu, et al.. (2013). Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1. Oncology Reports. 29(6). 2181–2190. 63 indexed citations

15.

Hao, Zhonglin, Thomas A. Dillard, Paul D. Biddinger, & Vijay Patel. (2013). Suppression of respiratory papillomatosis with malignant transformation by erlotinib in a kidney transplant recipient. BMJ Case Reports. 2013. bcr2013008757–bcr2013008757. 3 indexed citations

16.

Hao, Zhonglin, Hui Zhang, & John K. Cowell. (2011). Ubiquitin-conjugating enzyme UBE2C: molecular biology, role in tumorigenesis, and potential as a biomarker. Tumor Biology. 33(3). 723–730. 108 indexed citations

17.

Xu, Bingfang, Zhonglin Hao, Kula N. Jha, et al.. (2008). TSKS concentrates in spermatid centrioles during flagellogenesis. Developmental Biology. 319(2). 201–210. 25 indexed citations

18.

Xu, Bingfang, Zhonglin Hao, Kula N. Jha, et al.. (2008). Targeted deletion of Tssk1 and 2 causes male infertility due to haploinsufficiency. Developmental Biology. 319(2). 211–222. 84 indexed citations

19.

Kurth, Barbara E., Laura Digilio, Leigh Ann Bush, et al.. (2007). Immunogenicity of a multi-component recombinant human acrosomal protein vaccine in female Macaca fascicularis. Journal of Reproductive Immunology. 77(2). 126–141. 21 indexed citations

20.

Wright, Paul W., Laura Bolling, Meredith Calvert, et al.. (2003). ePAD, an oocyte and early embryo-abundant peptidylarginine deiminase-like protein that localizes to egg cytoplasmic sheets. Developmental Biology. 256(1). 74–89. 124 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact